Bupropion for adults with attention‐deficit hyperactivity disorder: Meta‐analysis of randomized, placebo‐controlled trials

  title={Bupropion for adults with attention‐deficit hyperactivity disorder: Meta‐analysis of randomized, placebo‐controlled trials},
  author={Narong Maneeton and Benchalak Maneeton and Manit Srisurapanont and Stephen D. Martin},
  journal={Psychiatry and Clinical Neurosciences},
Aim:  The aim of this study was to systematically review the efficacy, acceptability and tolerability of bupropion in comparison to placebo. Only randomized‐controlled trials were included in the meta‐analysis. 
Bupropion versus methylphenidate in the treatment of children with attention‐deficit/hyperactivity disorder: randomized double‐blind study
To compare the safety and efficacy of bupropion with methylphenidate in children and adolescents with attention‐deficit/hyperactivity disorder (ADHD).
The Revised Korean Practice Parameter for the Treatment of Attention-Deficit Hyperactivity Disorder (IV) - Non-Pharmacologic Treatment -
This practice parameter for non-pharmacological treatment for attention-deficit hyperactivity disorder (ADHD) review the domestic and international literature on the psychosocial treatment of
Bupropion in adults with Attention-Deficit/Hyperactivity Disorder: a randomized, double-blind study.
Bupropion can be an alternative medication for the treatment of Adults with ADHD as its clinical efficacy was proven by other studies and its theoretical and experimental evidence exists to support efficacy of this medication.
A systematic review of randomized controlled trials of bupropion versus methylphenidate in the treatment of attention-deficit/hyperactivity disorder
Based on limited data, bupropion was as effective as methylphenidate for ADHD patients and tolerability and acceptability were also comparable, however, these findings should be considered as very preliminary results.
Efficacy, safety and variability in pharmacotherapy for adults with attention deficit hyperactivity disorder: a meta-analysis and meta-regression in over 9000 patients
Pharmacological treatment provides mild symptom improvement but is associated with frequent AEs and higher treatment discontinuation than placebo, particularly when no concomitant psychotherapy is administered, and Stimulants appear more efficacious than non-stimulant drugs and the former should be preferred over the latter.
Comparative efficacy, acceptability, and tolerability of dexmethylphenidate versus placebo in child and adolescent ADHD: a meta-analysis of randomized controlled trials
It can be concluded that d- MPH medication is efficacious and tolerable in child and adolescent ADHD, however, the acceptability of d-MPH is no greater than that of the placebo.
Risks and Benefits of Bupropion Treatment in Schizophrenia: A Systematic Review of the Current Literature
In schizophrenic patients treated with buPropion in addition to antipsychotics, the risk for bupropion-induced psychoses seems negligible and the efficacy of a combined dopamine and norepinephrine agonist in schizophrenia is biologically plausible.
Efficacy, tolerability, and acceptability of bupropion for major depressive disorder: a meta-analysis of randomized–controlled trials comparison with venlafaxine
Bupropion XL is as effective and tolerable as venlafaxine XR for adult patients with MDD, according to the limited data obtained from three RCTs.
Bupropion for attention deficit hyperactivity disorder (ADHD) in adults.
Low-quality evidence that bupropion decreased the severity of ADHD symptoms and increased the proportion of participants achieving clinical improvement is found, suggesting a possible benefit in clinical improvement in adults with ADHD.
Psychopharmacology and psychotherapy for the treatment of adults with ADHD—a systematic review of available meta-analyses
The available meta-analytic literature does not cover questions of essential clinical relevance for adults with ADHD, and results suggest that stimulants are effective in decreasing ADHD symptoms on a short-term basis with a medium to large effect size (ES).


Bupropion XL in adults with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled study
Bupropion SR in adults with ADHD: a short-term, placebo-controlled trial
This short-term, double-blind trial was designed to evaluate the extended-release form of bupropion in adult subjects meeting DSM-IV and the Utah Diagnostic Criteria for ADHD, and favored buPropion SR over placebo, but achieved statistical significance on only one, post hoc measure.
A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults.
The results suggest a therapeutic role for bupropion in the armamentarium of agents for ADHD in adults, while further validating the continuity of pharmacological responsivity of ADHD across the lifespan.
Bupropion SR vs. Methylphenidate vs. Placebo for Attention Deficit Hyperactivity Disorder in Adults
  • S. Kuperman, P. Perry, Jane S. Paulsen
  • Psychology, Medicine
    Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists
  • 2001
Despite the increasing recognition of attention-deficit hyperactivity disorder (ADHD) in adults, there are few controlled trials demonstrating the effectiveness of pharmacological treatments,
Atomoxetine treatment in adults with attention‐deficit/hyperactivity disorder and comorbid social anxiety disorder
ATX monotherapy effectively improved symptoms of ADHD and comorbid social anxiety disorder in adults and was well tolerated.
Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder.
Results in adults with ADHD indicate that desipramine is effective in the treatment of ADHD in adults, similar to findings in children and adolescents with ADHD.
Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies
Antidepressants in the treatment of adult attention-deficit hyperactivity disorder: a systematic review
Although there is a need for alternative interventions for the treatment of ADHD, such as with antidepressant agents, the evidence base is not large and only treatment with bupropion seems to have a medium-range effect size, but this is less than that of stimulant medications.
Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis
Current best evidence supports using immediate release methylphenidate as first-line treatment for most adults with ADHD, and key gaps in evidence were academic, occupational, social functioning, cardiovascular toxicity, and longer-term outcomes.